Elicio Therapeutics旗下Amplify-7P二期研究未达到意向治疗人群的主要无病生存期终点

美股速递
Jun 15

Elicio Therapeutics公司宣布,其针对Amplify-7P项目进行的二期临床试验,在预先设定的意向治疗人群分析中,未能达到主要终点指标——无病生存期。这一结果标志着该候选疗法的关键临床开发遭遇挫折。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10